ELAN
Price
$26.48Alerts
Change
-$0.28 (-1.05%)
Updated
Nov 11, 04:59 PM (EDT)
Capitalization
12.86B
111 days until earnings call
Intraday BUY SELL Signals
TEVA
Price
$43.22Alerts
Change
+$0.82 (+1.93%)
Updated
Nov 11, 04:59 PM (EDT)
Capitalization
49.7B
91 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ELAN vs TEVA

ELAN vs TEVA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ELAN vs. TEVA commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAN is a Hold and TEVA is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ELAN with price predictions
Nov 10, 2026

Aroon Indicator for ELAN shows an upward move is likely

ELAN's Aroon Indicator triggered a bullish signal on November 10, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 207 similar instances where the Aroon Indicator showed a similar pattern. In 179 of the 207 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on ELAN as a result. In 52 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.

ELAN moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ELAN crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.

Following a +13.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where ELAN advanced for three days, in 174 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELAN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

ELAN broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. ELAN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.952) is normal, around the industry mean (6.379). P/E Ratio (-62.780) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (4.042) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (2.275) is also within normal values, averaging (183.387).

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELAN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

A.I.Advisor
a Summary for TEVA with price predictions
Nov 10, 2026

TEVA's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for TEVA turned positive on November 03, 2026. Looking at past instances where TEVA's MACD turned positive, the stock continued to rise in 32 of 40 cases over the following month. The odds of a continued upward trend are 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on TEVA as a result. In 56 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.

Following a +2.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where TEVA advanced for three days, in 229 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

The Aroon Indicator entered an Uptrend today. In 208 of 282 cases where TEVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.

TEVA broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. TEVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 72 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.410) is normal, around the industry mean (6.379). P/E Ratio (68.726) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.980) is also within normal values, averaging (2.202). Dividend Yield (0.008) settles around the average of (0.062) among similar stocks. P/S Ratio (2.589) is also within normal values, averaging (183.387).

FUNDAMENTALS RATINGS
ELAN vs TEVA: Fundamental Ratings
ELAN
TEVA
OUTLOOK RATING
1..100
2779
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
77
Overvalued
PROFIT vs RISK RATING
1..100
1006
SMR RATING
1..100
9272
PRICE GROWTH RATING
1..100
3938
P/E GROWTH RATING
1..100
987
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ELAN's Valuation (46) in the Agricultural Commodities Or Milling industry is in the same range as TEVA (77) in the Pharmaceuticals Generic industry. This means that ELAN’s stock grew similarly to TEVA’s over the last 12 months.

TEVA's Profit vs Risk Rating (6) in the Pharmaceuticals Generic industry is significantly better than the same rating for ELAN (100) in the Agricultural Commodities Or Milling industry. This means that TEVA’s stock grew significantly faster than ELAN’s over the last 12 months.

TEVA's SMR Rating (72) in the Pharmaceuticals Generic industry is in the same range as ELAN (92) in the Agricultural Commodities Or Milling industry. This means that TEVA’s stock grew similarly to ELAN’s over the last 12 months.

TEVA's Price Growth Rating (38) in the Pharmaceuticals Generic industry is in the same range as ELAN (39) in the Agricultural Commodities Or Milling industry. This means that TEVA’s stock grew similarly to ELAN’s over the last 12 months.

TEVA's P/E Growth Rating (7) in the Pharmaceuticals Generic industry is significantly better than the same rating for ELAN (98) in the Agricultural Commodities Or Milling industry. This means that TEVA’s stock grew significantly faster than ELAN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ELANTEVA
RSI
ODDS (%)
Bearish Trend 2 days ago
59%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
62%
Momentum
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
72%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 3 days ago
67%
Bullish Trend 3 days ago
76%
Declines
ODDS (%)
Bearish Trend 22 days ago
76%
Bearish Trend 7 days ago
66%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
61%
Bearish Trend 2 days ago
67%
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
74%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (ELAN: $26.76 vs. TEVA: $42.40)
Brand notoriety: ELAN and TEVA are both notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ELAN: 95% vs. TEVA: 100%
Market capitalization -- ELAN: $12.86B vs. TEVA: $49.7B
ELAN [@Pharmaceuticals: Generic] is valued at $12.86B. TEVA’s [@Pharmaceuticals: Generic] market capitalization is $49.7B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELAN’s FA Score shows that 0 FA rating(s) are green while TEVA’s FA Score has 2 green FA rating(s).

  • ELAN’s FA Score: 0 green, 5 red.
  • TEVA’s FA Score: 2 green, 3 red.
According to our system of comparison, TEVA is a better buy in the long-term than ELAN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELAN’s TA Score shows that 5 TA indicator(s) are bullish while TEVA’s TA Score has 4 bullish TA indicator(s).

  • ELAN’s TA Score: 5 bullish, 4 bearish.
  • TEVA’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, both ELAN and TEVA are a good buy in the short-term.

Price Growth

ELAN (@Pharmaceuticals: Generic) experienced а +8.91% price change this week, while TEVA (@Pharmaceuticals: Generic) price change was +1.17% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.20%. For the same industry, the average monthly price growth was -6.54%, and the average quarterly price growth was +10.31%.

Reported Earning Dates

ELAN is expected to report earnings on Mar 02, 2027.

TEVA is expected to report earnings on Feb 10, 2027.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.20% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
Interact to see
Advertisement

ELAN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELAN has been loosely correlated with PAHC. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ELAN jumps, then PAHC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELAN
1D Price
Change %
ELAN100%
-0.30%
PAHC - ELAN
52%
Loosely correlated
+0.09%
ZTS - ELAN
47%
Loosely correlated
+0.17%
SNDL - ELAN
39%
Loosely correlated
-0.71%
PRGO - ELAN
36%
Loosely correlated
-0.71%
VTRS - ELAN
34%
Loosely correlated
+1.76%
More

TEVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TEVA has been loosely correlated with AMRX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if TEVA jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TEVA
1D Price
Change %
TEVA100%
-1.33%
AMRX - TEVA
40%
Loosely correlated
+0.47%
VTRS - TEVA
35%
Loosely correlated
+1.76%
COLL - TEVA
28%
Poorly correlated
-0.97%
SNDL - TEVA
26%
Poorly correlated
-0.71%
ELAN - TEVA
26%
Poorly correlated
-0.30%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
PEPE.X0.000005N/A
+4.82%
Pepe cryptocurrency
SAGA.X0.0157270.000245
+1.59%
Saga cryptocurrency
FLUX.X0.052707-0.000113
-0.21%
Flux cryptocurrency
BTCST.X0.009436-0.000130
-1.36%
Bitcoin Standard Hashrate Token cryptocurrency
ZRX.X0.087713-0.001339
-1.50%
0x Protocol cryptocurrency